XARELTO Drug Patent Profile

When do Xarelto patents expire, and when can generic versions of Xarelto launch?

Xarelto is a drug marketed by Janssen Pharms and is included in two NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has twenty-nine patent family members in twenty-five countries.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the rivaroxaban profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xarelto

A generic version of XARELTO was approved as rivaroxaban by LUPIN on March 3^rd, 2025.

Summary for XARELTO

International Patents:	29
US Patents:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	92
Clinical Trials:	128
Patent Applications:	5,099
Drug Prices:	Drug price information for XARELTO
Drug Sales Revenues:	Drug sales revenues for XARELTO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XARELTO
What excipients (inactive ingredients) are in XARELTO?	XARELTO excipients list
DailyMed Link:	XARELTO at DailyMed

See drug prices for XARELTO

See drug sales revenues for XARELTO

Recent Clinical Trials for XARELTO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
U.S. Food and Drug Administration (FDA)	PHASE4
VA Office of Research and Development	PHASE4
Prof. Stavros Konstantinides, MD	PHASE3

See all XARELTO clinical trials

Pharmacology for XARELTO

Drug Class	Factor Xa Inhibitor
Mechanism of Action	Factor Xa Inhibitors

Paragraph IV (Patent) Challenges for XARELTO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XARELTO	Capsules	rivaroxaban	10 mg, 15 mg and 20 mg	022406	1	2022-06-17
XARELTO	Tablets	rivaroxaban	2.5 mg	022406	4	2018-11-19
XARELTO	Tablets	rivaroxaban	10 mg, 15 mg, and 20 mg	022406	8	2015-07-01

US Patents and Regulatory Information for XARELTO

XARELTO is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	XARELTO	rivaroxaban	FOR SUSPENSION;ORAL	215859-001	Dec 20, 2021	AB	RX	Yes	Yes
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-002	Nov 4, 2011	AB	RX	Yes	No	9,539,218*PED				Y
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-004	Oct 11, 2018	AB	RX	Yes	No
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011	AB	RX	Yes	No	9,539,218*PED				Y

Expired US Patents for XARELTO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-002	Nov 4, 2011	7,592,339
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-004	Oct 11, 2018	7,585,860
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011	7,585,860
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-002	Nov 4, 2011	7,585,860

EU/EMA Drug Approvals for XARELTO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Rivaroxaban Accord	rivaroxaban	EMEA/H/C/005279Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	yes	no	no	2020-11-16
Mylan Ireland Limited	Rivaroxaban Viatris (previously Rivaroxaban Mylan)	rivaroxaban	EMEA/H/C/005600Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. ------Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.-------Adults Prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	yes	no	no	2021-11-12
Bayer AG	Xarelto	rivaroxaban	EMEA/H/C/000944Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	no	no	no	2008-09-30

International Patents for XARELTO

See the table below for patents covering XARELTO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	032436	OXAZOLIDINONAS SUBSTITUIDAS, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS, EL USO DE LAS MISMAS PARA LA FABRICACION DE MEDICAMENTOS, Y EL METODO PARA IMPEDIR LA COAGULACION SANGUINEA IN VITRO
Austria	289605
Australia	2004218729
Australia	2841401

Supplementary Protection Certificates for XARELTO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1261606	91497	Luxembourg		91497, EXPIRES: 20230930
1261606	PA2008018	Lithuania		PRODUCT NAME: RIVAROXABANUM; REG. NO/DATE: EU/1/07/472/001-008 20080930
1261606	CA 2008 00050	Denmark		PRODUCT NAME: RIVAROXABAN OG DETS FARMACEUTISK ACCEPTABLE SALTE, HYDRATER, HYDRATER AF SALTENE OG PRODRUGS
1261606	300370	Netherlands

Xarelto (rivaroxaban) Market Dynamics and Financial Trajectory: Revenues, Growth Drivers, and Generic/Biosimilar Risk

Last updated: July 22, 2026

Executive summary: Xarelto (rivaroxaban) has moved from rapid expansion toward more mature growth, with performance increasingly driven by share capture in direct oral anticoagulant (DOAC) cohorts, geographic mix, and ongoing line extensions (dose/formulation) while facing intensifying competitive pricing pressure. Financial trajectory is shaped by (1) patent and exclusivity-driven generic entry timing across key markets, (2) competitor DOAC dynamics (Eliquis, Pradaxa, and generic DOACs), and (3) payer formulary and contracting trends. Below is a market-and-finance map focused on revenue exposure, competitive and regulatory catalysts, and the specific patent and entry mechanics that govern downside risk.

---

How has Xarelto’s revenue evolved since launch?

Featured answer: Xarelto’s revenue peaked during the middle-to-late 2010s as DOAC adoption accelerated, then shifted to slower growth as competition increased and generic erosion expanded in later years. The trajectory is consistent with “category leader” behavior: early growth through new-to-brand substitution, followed by margin compression from pricing pressure and later generic penetration.

What revenue drivers mattered most

1. DOAC category uptake
   Xarelto grew with expansion of oral anticoagulation in atrial fibrillation (AF), venous thromboembolism (VTE) treatment and prophylaxis, and post-acute settings where DOAC convenience shifted prescribing patterns.

2. Indication expansion within the label
   Xarelto’s commercial curve tracked incremental prescriber comfort and reimbursement coverage for additional dose regimens aligned to AF stroke prevention and VTE strategies.

3. Geographic rollouts and formulary position
   Higher penetration in the US and EU markets and favorable formulary placement drove sustained prescription volume even as competition increased.

What revenue constraints emerged

1. Pricing and contracting pressure As DOACs became standard of care, payer negotiations increasingly anchored to the lowest-cost therapeutically equivalent options, pushing list price and net price down.

2. Generic erosion Once generic rivaroxaban entered key markets (timing varies by geography and regulatory status), the economics shifted from brand premium to volume-based share and lower net pricing.

3. Comparative efficacy and switching Eliquis and Pradaxa competitive positioning influenced switch rates, particularly when pricing or coverage favored rivals.

---

What is Xarelto’s biggest market segment exposure (AF vs VTE)?

Featured answer: The AF segment is typically the largest and most durable revenue lever, with VTE-related indications acting as additional volume and growth contributors. Xarelto’s commercial engine is tied to long-duration chronic use in AF and acute-to-chronic transitions in VTE pathways.

AF exposure: Why it matters for financial stability

• Chronic therapy profile supports recurring demand.
• Prescriber inertia exists once patients are established on a DOAC, but switching is common when pricing/coverage changes.
• Risk stratification drives dose usage patterns that affect relative demand within the label.

VTE exposure: Why it can be more volatile

• Event-driven demand causes seasonality and case variability.
• Hospital and post-discharge pathways can shift with guideline adoption and local care pathways.

---

How does competition among DOACs affect Xarelto’s pricing and share?

Featured answer: DOAC competition compresses net pricing and shifts share through formulary placement and patient out-of-pocket dynamics. The competitive set is primarily apixaban (Eliquis), dabigatran (Pradaxa), and their generic counterparts where available.

Competitive mechanism by channel

1. Payer contracting

   • Preferred formulary status reduces prescribing friction.
   • Step-therapy and cost-sharing drives switching.

2. Provider practice patterns

   • Once a DOAC is “defaulted” in a system, switching requires clinical justification or payer pressure.

3. Sales and education

   • Clinical support and pathway marketing can influence adoption and persistence, but economic factors increasingly dominate.

Financial impact channel

• Net price decline shows up faster than volume in mature markets.
• Share erosion can follow generic availability and competitive contracts.

---

When does generic rivaroxaban erode Xarelto exclusivity in key markets?

Featured answer: Generic erosion timing is controlled by patent expiry, exclusivity windows, and litigation outcomes that affect whether a first generic can launch earlier. For rivaroxaban, the market typically transitions from “brand premium” to a mixed brand-plus-generic environment once the first approved generic or authorized generic launches.

US mechanics to watch for erosion

• ANDA approvals with Paragraph IV certifications drive settlement and launch timing.
• 180-day exclusivity for a first filer can delay follow-on generics.
• Authorized generics can accelerate price pressure without branded patent risk for a competitor.

EU and UK dynamics

• National patent enforcement and local SPC (supplementary protection certificate) outcomes can extend exclusivity differently across markets.
• Local generic filing pace controls how quickly market share and pricing shift after expiry.

---

What patents protect Xarelto and how strong is the estate against generics?

Featured answer: Xarelto’s patent estate has historically encompassed active-ingredient composition, pharmaceutical compositions/formulations, and sometimes specific manufacturing or use claims tied to labeled dosing strategies. Strength and remaining term vary by jurisdiction and claim scope, affecting the likelihood of early generic entry or design-around.

Common claim buckets that matter commercially

1. Composition of matter (rivaroxaban itself)

   • Usually central for baseline exclusivity.

2. Formulation patents

   • Cover release characteristics and specific dosage forms (important because generic applicants must match to avoid infringement).

3. Method-of-use and dosing regimen patents

   • Affect whether generics can be marketed for the same labeled indications and dosing without a carve-out or additional litigation.

4. Device or administration system claims

   • Less common for oral anticoagulants, but relevant where covered.

How estate strength maps to financial outcomes

• Strong formulation/use claims can delay “true” market competition by restricting launch labeling.
• Narrow claims lead to partial entry scenarios that reduce brand revenue less than full-label generic launches.

---

What is the Orange Book status of Xarelto and what does it mean for Paragraph IV risk?

Featured answer: The Orange Book listing defines which Xarelto-related patents a generic must address to seek FDA approval with Paragraph IV certifications. Patent landscape determines whether generic entry triggers litigation, settlement, or design-around.

Orange Book-driven risk signals

• Multiple listed patents with different expiration dates create staggered risk points.
• Method-of-use or formulation listings can produce “label carving” dynamics.
• Hatch-Waxman litigation outcomes can delay approval or constrain launch timing.

---

What Xarelto patent litigation affects generic launch timing?

Featured answer: The biggest financial effect comes from whether generic applicants win early, lose, or settle. Settlements typically include agreed launch dates, non-infringement outcomes, or market allocation constraints.

Typical litigation outcomes that change financial trajectory

1. Early dismissal or non-infringement

   • Creates immediate downside risk to branded pricing.

2. Injunction or adverse judgment

   • Delays generic launch and sustains brand economics.

3. Settlement agreements

   • Often lock in launch dates or label restrictions.

How to interpret litigation for forecasting

• Settlements shift revenue timing more than they change long-term category growth.
• The first credible generic entry tends to drive the initial price compression, with follow-ons deepening erosion.

---

How does Xarelto financial performance compare with Eliquis and Pradaxa?

Featured answer: In the DOAC category, Eliquis (apixaban) has often demonstrated stronger sustained volume and share in parts of the market, while Xarelto’s performance has been more sensitive to generic erosion and payer pricing. Pradaxa competes strongly in segments where prescriber preference or dosing characteristics align with coverage.

Side-by-side commercial variables that control relative revenue

• Net price trend after generic entry by geography
• Formulary preference and coverage breadth by insurer group
• Switch rates and adherence/persistence in AF
• Hospital and specialty channel penetration

---

How do formulation and dosage variants affect Xarelto revenue resilience?

Featured answer: Dose variants and formulation-specific value protect revenue longer by slowing direct substitution. Each additional covered product variant can sustain branded share by preserving clinically approved dosing patterns or by complicating “label-complete” generic launch.

Key commercial implications of formulation differentiation

• Generics may launch with limited label scope if specific formulation/use claims remain enforced.
• Authorized generics or fully label-matched generics reduce the brand buffer faster.

---

What biosimilar risk applies to Xarelto?

Featured answer: Biosimilar risk does not apply in the same way as for biologics because Xarelto is a small-molecule anticoagulant. Competitive risk comes from generic small molecules and authorized generics, not biosimilar mechanisms.

---

What manufacturing and supply-chain risks matter for Xarelto’s financial trajectory?

Featured answer: For a mature brand like Xarelto, financial risk is less about clinical manufacturing failure and more about meeting demand during transition periods (brand-to-generic) and maintaining cost competitiveness under pricing compression.

Where operational costs show up

• API and drug product sourcing
• Scale economics when demand shifts
• Quality system disruptions that can tighten supply and raise per-unit cost

---

What regulatory timeline milestones influence future Xarelto earnings?

Featured answer: The most relevant regulatory milestones are FDA approval of generics/authorized generics, court outcomes affecting launch timing, and label changes tied to dosing updates. These can reprice the market quickly.

US-centered milestones with earnings impact

• ANDA approvals for generic rivaroxaban
• Court rulings that unlock or delay launch
• Settlement effective dates

Global milestones

• National SPC expiries
• Local court enforcement
• Marketing authorization of generics by country

---

Generic entry scenarios: how much downside can Xarelto face after loss of exclusivity?

Featured answer: Downside scales with (1) how quickly multiple generic entrants appear, (2) whether an authorized generic is used, and (3) whether payer contracts switch from brand-preferred to generic-preferred formularies immediately.

Scenario framework for forecasting net revenue erosion

Scenario	Entry pattern	Typical market effect	Earnings implication
Limited first-generic	Single entrant, possible 180-day exclusivity window	Slower price compression, share loss concentrated	Moderate decline; margin may drop before volume fully erodes
Rapid multi-generic	Multiple ANDAs launch together or authorized generic enters	Faster list-to-net repricing and strong share shift	Steeper revenue and margin decline
Label-restricted entry	Launch with carve-outs due to use/formulation constraints	Brand holds portions of usage	Lower near-term revenue downside, longer tail

---

Key financial trajectory drivers and watch-list for investors and business planners

Featured answer: The dominant variables are generic launch calendars (driven by patent status and litigation), net price trend from payer contracting, and persistent share in AF and VTE dosing cohorts.

Business-critical watch list

• Patent expiry calendar by geography and claim type (composition vs formulation vs method-of-use)
• Litigation and settlement effective dates tied to launch restrictions
• FDA ANDA approvals and labeling scope
• Formulary movement among large payer systems
• Net price trend versus list price and mix

---

Key Takeaways

• Xarelto’s financial trajectory has followed a typical DOAC pattern: early category growth, then maturity with increasing pricing pressure.
• Revenue stability depends on AF chronic demand, payer formulary positioning, and resistance to immediate generic substitution through patent constraints.
• The primary earnings downside risk is generic rivaroxaban entry timing, intensity, and label completeness.
• Litigation outcomes and settlement agreements govern launch timing and therefore the slope of revenue erosion.
• Biosimilar risk is not a direct issue; competitive risk is generic and authorized generic entry.

---

FAQs

1. What factors accelerate net price declines for Xarelto after generic launch?
   Payer contracting speed, authorized generic presence, number of simultaneous generic entrants, and formulary switching timing.

2. How do method-of-use patents affect generic competition for Xarelto?
   They can restrict the generic’s ability to market for certain labeled indications or dosing regimens, enabling label carving and slower erosion.

3. Does Xarelto face biosimilar competition in anticoagulation?
   No. Xarelto is a small molecule; the competitive threat is generic rivaroxaban (and authorized generics), not biosimilars.

4. Which DOAC rivalry most pressures Xarelto’s AF share and prescribing?
   Apixaban (Eliquis) and the competitive impact of generic DOAC availability, mediated through formulary preferences and cost-sharing.

5. What Orange Book events most influence the next Xarelto downside window?
   New Orange Book patent listings that add Paragraph IV risk, and patent expiration dates coupled with active litigation and settlement schedules.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Xarelto (rivaroxaban). FDA.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (rivaroxaban). FDA.
3. Bloomberg (Industry). (n.d.). DOAC category and payer dynamics coverage.

DrugChatter Q&A for XARELTO

When is xarelto's patent set to expire roughly?
Xarelto tab 20mg patent expiry date?
Xarelto patent release date?
Is xarelto going generic in 2026?
Xarelto loss of exclusivity date?